PMID- 35337110
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220329
IS  - 1424-8247 (Print)
IS  - 1424-8247 (Electronic)
IS  - 1424-8247 (Linking)
VI  - 15
IP  - 3
DP  - 2022 Mar 4
TI  - Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular 
      Disease, Cancer and Dementia.
LID - 10.3390/ph15030312 [doi]
LID - 312
AB  - The biguanide metformin has been used as first-line therapy in type 2 diabetes 
      mellitus (T2DM) treatment for several decades. In addition to its 
      glucose-lowering properties and its prevention of weight gain, the landmark UK 
      Prospective Diabetes Study (UKPDS) demonstrated cardioprotective properties in 
      obese T2DM patients. Coupled with a favorable side effect profile and low cost, 
      metformin has become the cornerstone in the treatment of T2DM worldwide. In 
      addition, metformin is increasingly being investigated for its potential 
      anticancer and neuroprotective properties both in T2DM patients and non-diabetic 
      individuals. In the meantime, new drugs with powerful cardioprotective properties 
      have been introduced and compete with metformin for its place in the treatment of 
      T2DM. In this review we will discuss actual insights in the various working 
      mechanisms of metformin and the evidence for its beneficial effects on (the 
      prevention of) cardiovascular disease, cancer and dementia. In addition to 
      observational evidence, emphasis is placed on randomized trials and recent 
      meta-analyses to obtain an up-to-date overview of the use of metformin in 
      clinical practice.
FAU - Top, Wiebe M C
AU  - Top WMC
AD  - Department of Intensive Care, Treant Care Group, 7909 AA Hoogeveen, The 
      Netherlands.
FAU - Kooy, Adriaan
AU  - Kooy A
AUID- ORCID: 0000-0002-8853-0019
AD  - Department of Internal Medicine, Treant Care Group, 7909 AA Hoogeveen, The 
      Netherlands.
AD  - Bethesda Diabetes Research Center, 7909 AA Hoogeveen, The Netherlands.
AD  - Department of Internal Medicine, University Medical Center Groningen, 9713 GZ 
      Groningen, The Netherlands.
FAU - Stehouwer, Coen D A
AU  - Stehouwer CDA
AD  - Department of Internal Medicine, Cardiovascular Research Institute Maastricht, 
      Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220304
PL  - Switzerland
TA  - Pharmaceuticals (Basel)
JT  - Pharmaceuticals (Basel, Switzerland)
JID - 101238453
PMC - PMC8951049
OTO - NOTNLM
OT  - cancer
OT  - cardiovascular diseases
OT  - dementia
OT  - diabetes
OT  - metformin
OT  - pleiotropic effect
COIS- The authors declare no conflict of interest.
EDAT- 2022/03/27 06:00
MHDA- 2022/03/27 06:01
PMCR- 2022/03/04
CRDT- 2022/03/26 01:08
PHST- 2022/02/10 00:00 [received]
PHST- 2022/02/28 00:00 [revised]
PHST- 2022/03/01 00:00 [accepted]
PHST- 2022/03/26 01:08 [entrez]
PHST- 2022/03/27 06:00 [pubmed]
PHST- 2022/03/27 06:01 [medline]
PHST- 2022/03/04 00:00 [pmc-release]
AID - ph15030312 [pii]
AID - pharmaceuticals-15-00312 [pii]
AID - 10.3390/ph15030312 [doi]
PST - epublish
SO  - Pharmaceuticals (Basel). 2022 Mar 4;15(3):312. doi: 10.3390/ph15030312.